BioSpace News Archive

Deals

Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8

Five Prime Therapeutics, Inc. will report its first quarter 2019 financial results on Wednesday, May 8, 2019, after the U.S. financial markets close.

April 17, 2019
·
1 min read
Drug Development

Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD

A First-in-Class Ophthalmological Recombinant Fully Human Bi-specific Fusion Protein Targeting VEGF and Complement Proteins

April 17, 2019
·
5 min read
BioForest

Declining Healthcare Affordability for Medically Underserved Populations is Traceable to Revenue-Maximizing Policy Decisions by 340B Hospitals & Pharmacies

It is less likely that a person in poverty and without year-round health insurance is able to afford needed prescription drugs than a similarly situated person ten years ago.

April 17, 2019
·
2 min read
Policy

United Therapeutics Issues Statement In Response To Meritless Lawsuit

United Therapeutics Corporation was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc.

April 17, 2019
·
6 min read
Deals

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock - April 17, 2019

Eiger BioPharmaceuticals, Inc. announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share.

April 17, 2019
·
4 min read
Deals

Natera Announces Pricing of Follow-On Offering - April 17, 2019

Natera, Inc. announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $19.00 per share.

April 17, 2019
·
2 min read
Drug Development

MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS

MediciNova, Inc. announced that the U.S. Food and Drug Administration has completed its review of the protocol and determined that MediciNova may proceed with a Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis.

April 17, 2019
·
7 min read
Drug Development

Polyphor announces enrollment of first patient in PRISM-UDR - the second, FDA agreed - Phase III clinical trial for murepavadin in patients with nosocomial pneumonia

Murepavadin is the lead, pathogen specific, Phase III antibiotic belonging to the OMPTA family and potentially the first drug of a new class of antibiotics against Gram-negative bacteria in more than 50 years

April 17, 2019
·
4 min read
Deals

BioArctic publishes the Annual Report for 2018

BioArctic AB announced that the Annual Report for the 2018 fiscal year has been published.

April 17, 2019
·
1 min read
Deals

CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform

CEVEC Pharmaceuticals GmbH announced the successful closing of a Series D financing round with new and existing investors.

April 17, 2019
·
3 min read